Ra Pharmaceuticals (NASDAQ:RARX) had its price objective lifted by stock analysts at BMO Capital Markets in a research note issued on Tuesday.

RARX has been the topic of several other reports. Zacks Investment Research upgraded shares of Ra Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, September 26th. Jefferies Group reiterated a “buy” rating and set a $25.00 price objective on shares of Ra Pharmaceuticals in a research report on Thursday, September 28th. Royal Bank Of Canada initiated coverage on shares of Ra Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $21.00 price objective on the stock. Finally, Credit Suisse Group lifted their price objective on shares of Ra Pharmaceuticals from $19.00 to $23.00 and gave the stock an “outperform” rating in a research report on Friday, November 10th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Ra Pharmaceuticals has a consensus rating of “Buy” and an average price target of $23.80.

Ra Pharmaceuticals (NASDAQ RARX) opened at $8.92 on Tuesday. Ra Pharmaceuticals has a 52-week low of $8.45 and a 52-week high of $27.84.

Ra Pharmaceuticals (NASDAQ:RARX) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.06). analysts anticipate that Ra Pharmaceuticals will post -2.46 earnings per share for the current year.

Several large investors have recently modified their holdings of the business. VHCP Management II LLC boosted its stake in shares of Ra Pharmaceuticals by 6.2% during the 2nd quarter. VHCP Management II LLC now owns 769,771 shares of the company’s stock valued at $14,426,000 after buying an additional 44,742 shares during the period. Tekla Capital Management LLC acquired a new stake in shares of Ra Pharmaceuticals during the 2nd quarter valued at $7,418,000. Vanguard Group Inc. boosted its stake in shares of Ra Pharmaceuticals by 28.3% during the 2nd quarter. Vanguard Group Inc. now owns 346,602 shares of the company’s stock valued at $6,496,000 after buying an additional 76,349 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Ra Pharmaceuticals during the 3rd quarter valued at $4,664,000. Finally, Sectoral Asset Management Inc boosted its stake in shares of Ra Pharmaceuticals by 55.6% during the 3rd quarter. Sectoral Asset Management Inc now owns 278,082 shares of the company’s stock valued at $4,060,000 after buying an additional 99,332 shares during the period. 69.64% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Ra Pharmaceuticals (RARX) Given New $0.00 Price Target at BMO Capital Markets” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/05/ra-pharmaceuticals-rarx-given-new-0-00-price-target-at-bmo-capital-markets.html.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Receive News & Ratings for Ra Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.